COMPREHENSIVE CROSS-DATABASE IDENTIFIER AND FUNCTIONAL MAPPING REFERENCE FOR HUMAN ALK
Section 1: Gene Identifiers
| Database | Identifier | Additional Info |
|---|
| HGNC ID | HGNC:427 | Approved |
| Approved Symbol | ALK | |
| Approved Name | ALK receptor tyrosine kinase | |
| Ensembl Gene | ENSG00000171094 | |
| NCBI Entrez Gene | 238 | protein-coding |
| OMIM | 105590 | |
| Locus Type | gene with protein product | |
| Locus Group | protein-coding gene | |
Aliases: CD246, ALK1
Previous Names: anaplastic lymphoma kinase (Ki-1), anaplastic lymphoma receptor tyrosine kinase
Gene Groups: Receptor tyrosine kinases, CD molecules
Genomic Location
| Attribute | Value |
|---|
| Chromosome | 2 |
| Cytogenetic Band | 2p23.2-p23.1 |
| Start Position | 29,192,774 |
| End Position | 29,921,586 |
| Strand | Minus (-) |
| Genome | GRCh38 (homo_sapiens) |
| Gene Length | 728,813 bp |
Section 2: Transcript Identifiers
Ensembl Transcripts (Total: 7)
| Transcript ID | Biotype | Start | End | Strand |
|---|
| ENST00000389048 | protein_coding | 29,192,774 | 29,921,586 | - |
| ENST00000431873 | nonsense_mediated_decay | 29,192,794 | 29,227,653 | - |
| ENST00000453137 | protein_coding | 29,220,870 | 29,223,394 | - |
| ENST00000498037 | protein_coding_CDS_not_defined | 29,286,410 | 29,319,211 | - |
| ENST00000618119 | protein_coding | 29,192,777 | 29,717,700 | - |
| ENST00000638605 | protein_coding_CDS_not_defined | 29,193,207 | 29,224,727 | - |
| ENST00000642122 | protein_coding | 29,192,774 | 29,223,900 | - |
RefSeq Transcripts (Human ALK)
| Accession | Type | Status | MANE Select |
|---|
| NM_004304 | mRNA | REVIEWED | ✓ YES (Canonical) |
| NM_001353765 | mRNA | REVIEWED | No |
RefSeq Proteins (Human ALK)
| Accession | Status | MANE Select |
|---|
| NP_004295 | REVIEWED | ✓ YES (Canonical) |
| NP_001340694 | REVIEWED | No |
CCDS Identifiers (Total: 2)
| CCDS ID |
|---|
| CCDS33172 |
| CCDS86828 |
Exons of Canonical Transcript ENST00000389048 (Total: 29)
| Exon ID | Start | End | Length |
|---|
| ENSE00001794937 | 29,919,993 | 29,921,586 | 1,594 |
| ENSE00001313023 | 29,717,578 | 29,717,697 | 120 |
| ENSE00001290865 | 29,694,850 | 29,695,014 | 165 |
| ENSE00001313033 | 29,531,915 | 29,532,116 | 202 |
| ENSE00001255693 | 29,383,732 | 29,383,859 | 128 |
| ENSE00001255673 | 29,328,350 | 29,328,481 | 132 |
| ENSE00001255668 | 29,320,751 | 29,320,882 | 132 |
| ENSE00003584441 | 29,318,304 | 29,318,404 | 101 |
| ENSE00003638382 | 29,296,888 | 29,297,057 | 170 |
| ENSE00001255625 | 29,275,099 | 29,275,227 | 129 |
| ENSE00001255635 | 29,275,402 | 29,275,496 | 95 |
| ENSE00001329399 | 29,251,105 | 29,251,267 | 163 |
| ENSE00001154433 | 29,239,680 | 29,239,830 | 151 |
| ENSE00001154428 | 29,233,565 | 29,233,696 | 132 |
| ENSE00001154426 | 29,232,304 | 29,232,448 | 145 |
| ENSE00001255591 | 29,228,884 | 29,229,066 | 183 |
| ENSE00001154420 | 29,227,574 | 29,227,672 | 99 |
| ENSE00001154417 | 29,226,922 | 29,227,074 | 153 |
| ENSE00001154411 | 29,225,461 | 29,225,565 | 105 |
| ENSE00001154407 | 29,223,342 | 29,223,528 | 187 |
| ENSE00001154403 | 29,222,517 | 29,222,607 | 91 |
| ENSE00001154399 | 29,222,344 | 29,222,408 | 65 |
| ENSE00001154395 | 29,220,706 | 29,220,835 | 130 |
| ENSE00001154390 | 29,213,984 | 29,214,081 | 98 |
| ENSE00001154381 | 29,209,786 | 29,209,878 | 93 |
| ENSE00001682043 | 29,207,171 | 29,207,272 | 102 |
| ENSE00001154367 | 29,197,542 | 29,197,676 | 135 |
| ENSE00001154361 | 29,196,770 | 29,196,860 | 91 |
| ENSE00001140354 | 29,192,774 | 29,193,922 | 1,149 |
Section 3: Protein Identifiers
UniProt Accessions
| Accession | Name | Status | Canonical |
|---|
| Q9UM73 | ALK tyrosine kinase receptor | Reviewed (Swiss-Prot) | ✓ YES |
Alternative Names: Anaplastic lymphoma kinase
Protein Properties:
| Property | Value |
|---|
| Length | 1,620 amino acids |
| Mass | 176,442 Da |
Protein Domains and Families (InterPro) - Total: 13
| InterPro ID | Name | Type |
|---|
| IPR000719 | Prot_kinase_dom | Domain |
| IPR000998 | MAM_dom | Domain |
| IPR001245 | Ser-Thr/Tyr_kinase_cat_dom | Domain |
| IPR002011 | Tyr_kinase_rcpt_2_CS | Conserved_site |
| IPR002172 | LDrepeatLR_classA_rpt | Repeat |
| IPR008266 | Tyr_kinase_AS | Active_site |
| IPR011009 | Kinase-like_dom_sf | Homologous_superfamily |
| IPR013320 | ConA-like_dom_sf | Homologous_superfamily |
| IPR017441 | Protein_kinase_ATP_BS | Binding_site |
| IPR020635 | Tyr_kinase_cat_dom | Domain |
| IPR036055 | LDL_receptor-like_sf | Homologous_superfamily |
| IPR050122 | RTK | Family |
| IPR055163 | ALK/LTK-like_GRD | Domain |
Section 4: Structure Identifiers
Experimental Structures (PDB) - Total: 79
| PDB ID | Title | Method | Resolution (Å) |
|---|
| 2KUP | Complex of PTB domain of SNT-2 and HALK peptide | NMR | - |
| 2KUQ | Chimera of PTB domain of SNT-2 and HALK peptide | NMR | - |
| 2XB7 | ALK in complex with NVP-TAE684 | X-ray | 2.50 |
| 2XBA | ALK in complex with PHA-E429 | X-ray | 1.95 |
| 2XP2 | ALK in complex with Crizotinib (PF-02341066) | X-ray | 1.90 |
| 2YFX | L1196M Mutant ALK with Crizotinib | X-ray | 1.70 |
| 2YHV | L1196M Mutant ALK | X-ray | 1.90 |
| 2YJR | F1174L Mutant ALK | X-ray | 1.90 |
| 2YJS | C1156Y Mutant ALK | X-ray | 1.90 |
| 3AOX | ALK with CH5424802 (Alectinib precursor) | X-ray | 1.75 |
| 3L9P | ALK Catalytic Domain | X-ray | 1.80 |
| 4ANL | G1269A Mutant ALK | X-ray | 1.70 |
| 4CLI | ALK with PF-06463922 (Lorlatinib) | X-ray | 2.05 |
| 4MKC | ALK with LDK378 (Ceritinib) | X-ray | 2.01 |
| 4Z55 | ALK with pyrazolopyrimidine derivative of LDK378 | X-ray | 1.55 |
| 5FTO | ALK with Entrectinib | X-ray | 2.22 |
| 6MX8 | ALK with Brigatinib | X-ray | 1.96 |
| 7LRZ | Human ALK GRD | X-ray | 1.91 |
| 7LS0 | Human ALK GRD bound to AUG | X-ray | 3.05 |
| 7MZW | ALK extracellular ligand binding region 673-1025 | NMR | - |
| 7MZY | ALK extracellular fragment 673-986 | X-ray | 1.50 |
| 7N00 | ALK extracellular 648-1025 with AUG-alpha | Cryo-EM | 2.27 |
| 7NWZ | ALK:ALKAL2 complex | X-ray | 4.17 |
| 9G5I | ALK:ALKAL2 complex (2:1) | Cryo-EM | 3.20 |
| 9GBE | ALK G1202R/L1196M with NVL-655 | X-ray | 1.58 |
(Plus 54 additional structures - showing representative subset)
Method Distribution: X-ray Diffraction (~70), NMR (~5), Cryo-EM (~4)
Predicted Structure (AlphaFold)
| Model ID | Sequence Length | Global pLDDT | Fraction Very High pLDDT |
|---|
| AF-Q9UM73-F1 | 12,397 | 68.26 | 0.20 (20%) |
Section 5: Cross-Species Orthologs
| Organism | Ensembl ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000055471 | Alk | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000008683 | Alk | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000095833 | alk | protein_coding |
| Fruit fly (Drosophila melanogaster) | FBGN0040505 | Alk | protein_coding |
| Worm (C. elegans) | No direct ortholog | - | - |
| Yeast (S. cerevisiae) | No ortholog | - | - |
Section 6: Clinical Variants & AI Predictions
ClinVar Summary
Total Variant Count: 6,175
| Classification | Count |
|---|
| Pathogenic | 19 |
| Likely Pathogenic | 7 |
| Uncertain Significance (VUS) | ~6,000+ |
| Likely Benign | ~50+ |
| Benign | ~100+ |
Pathogenic Variants (Total: 19)
| ClinVar ID | HGVS | Variant Type | Review Status |
|---|
| 18083 | c.3824G>A (p.Arg1275Gln) | SNV | Multiple submitters |
| 18085 | c.3575G>C (p.Arg1192Pro) | SNV | Single submitter |
| 217849 | c.3520T>C (p.Phe1174Leu) | SNV | No criteria |
| 217850 | c.3520T>A (p.Phe1174Ile) | SNV | No criteria |
| 65670 | c.3520T>G (p.Phe1174Val) | SNV | No criteria |
| 217851 | c.3522C>A (p.Phe1174Leu) | SNV | No criteria |
| 217852 | c.3522C>G (p.Phe1174Leu) | SNV | No criteria |
| 545115 | c.3512T>C (p.Ile1171Thr) | SNV | No criteria |
| 217855 | c.3733T>A (p.Phe1245Ile) | SNV | No criteria |
| 217856 | c.3734T>G (p.Phe1245Cys) | SNV | No criteria |
| 217857 | c.3735C>A (p.Phe1245Leu) | SNV | No criteria |
| 217858 | c.3833A>C (p.Tyr1278Ser) | SNV | No criteria |
| 1527803 | 2p23.2-21 deletion | CNV | Single submitter |
| 3247472 | Exon deletion | Deletion | Single submitter |
| 394466 | 2p23.2-21 gain | CNV | No criteria |
| 487484 | inv(2)(p23;p21) | Inversion | No criteria |
| 562660 | 2p23.2-22.3 loss | CNV | No criteria |
| 627530 | t(2;3)(p12;p14.3) | Translocation | No criteria |
| 687302 | 2p23.2-22.2 loss | CNV | No criteria |
Likely Pathogenic Variants (Total: 7)
| ClinVar ID | HGVS | Variant Type |
|---|
| 1705031 | c.3538G>C (p.Val1180Leu) | SNV |
| 217854 | c.3718T>G (p.Leu1240Val) | SNV |
| 2445401 | c.402G>C (p.Lys134Asn) | SNV |
| 375887 | c.3521T>G (p.Phe1174Cys) | SNV |
| 376135 | c.3586C>A (p.Leu1196Met) | SNV |
| 547174 | inv(2)(p21p23.2) | Inversion |
| 978809 | c.4298_4299del (p.Glu1433fs) | Deletion |
AlphaMissense Predictions
Total Predictions: 10,546
| Classification | Approximate Count |
|---|
| Likely Pathogenic | ~3,000+ |
| Ambiguous | ~4,000+ |
| Likely Benign | ~3,500+ |
TOP 50 Predicted Pathogenic Missense Variants (Highest Scores):
| Variant | Position | Score | Class |
|---|
| W1510R | 1510 | 0.998 | likely_pathogenic |
| G1508D | 1508 | 0.996 | likely_pathogenic |
| C1579W | 1579 | 0.994 | likely_pathogenic |
| G1508V | 1508 | 0.993 | likely_pathogenic |
| C1579R | 1579 | 0.993 | likely_pathogenic |
| C1579Y | 1579 | 0.992 | likely_pathogenic |
| S1509P | 1509 | 0.991 | likely_pathogenic |
| W1510C | 1510 | 0.991 | likely_pathogenic |
| G1508R | 1508 | 0.990 | likely_pathogenic |
| F1577S | 1577 | 0.990 | likely_pathogenic |
| F1577L | 1577 | 0.988 | likely_pathogenic |
| F1572L | 1572 | 0.976 | likely_pathogenic |
| C1579F | 1579 | 0.974 | likely_pathogenic |
| W1510S | 1510 | 0.969 | likely_pathogenic |
| F1511L | 1511 | 0.968 | likely_pathogenic |
| V1582D | 1582 | 0.966 | likely_pathogenic |
| G1580E | 1580 | 0.965 | likely_pathogenic |
| W1510G | 1510 | 0.964 | likely_pathogenic |
| S1509F | 1509 | 0.964 | likely_pathogenic |
| G1580V | 1580 | 0.957 | likely_pathogenic |
SpliceAI Predictions
Total Predictions: 6,693
High-Impact Splice Variants (Score ≥0.5): 100+ variants
TOP 50 High-Confidence Splice-Altering Variants:
| Variant | Effect | Delta Score |
|---|
| 2:29193928:G:C | acceptor_gain | 1.00 |
| 2:29196858:TAT:T | acceptor_gain | 1.00 |
| 2:29196859:AT:A | acceptor_gain | 1.00 |
| 2:29196764:TTTTA:T | donor_loss | 1.00 |
| 2:29196765:TTTA:T | donor_loss | 1.00 |
| 2:29196766:TTAC:T | donor_loss | 1.00 |
| 2:29196767:TACCT:T | donor_loss | 1.00 |
| 2:29196768:A:AT | donor_loss | 1.00 |
| 2:29196769:C:A | donor_loss | 1.00 |
| 2:29196861:CTAA:C | acceptor_loss | 1.00 |
| 2:29196859:ATCTA:A | acceptor_loss | 1.00 |
| 2:29193926:CCG:C | acceptor_gain | 0.99 |
| 2:29193927:C:T | acceptor_gain | 0.99 |
| 2:29196768:A:AC | donor_gain | 0.99 |
| 2:29196769:C:CC | donor_gain | 0.99 |
| 2:29196857:GTAT:G | acceptor_gain | 0.99 |
| 2:29193921:TCCTG:T | acceptor_loss | 0.98 |
| 2:29193923:C:CC | acceptor_gain | 0.98 |
| 2:29193928:G:GC | acceptor_gain | 0.98 |
| 2:29196856:GGTAT:G | acceptor_gain | 0.98 |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways (Total: 11)
| Pathway ID | Pathway Name | Disease Pathway |
|---|
| R-HSA-201556 | Signaling by ALK | No |
| R-HSA-9851151 | MDK and PTN in ALK signaling | No |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | Yes |
| R-HSA-9700645 | ALK mutants bind TKIs | Yes |
| R-HSA-9717326 | crizotinib-resistant ALK mutants | Yes |
| R-HSA-9717316 | alectinib-resistant ALK mutants | Yes |
| R-HSA-9717319 | brigatinib-resistant ALK mutants | Yes |
| R-HSA-9717323 | ceritinib-resistant ALK mutants | Yes |
| R-HSA-9717329 | lorlatinib-resistant ALK mutants | Yes |
| R-HSA-9717264 | ASP-3026-resistant ALK mutants | Yes |
| R-HSA-9717301 | NVP-TAE684-resistant ALK mutants | Yes |
Gene Ontology Annotations (Total: 29)
Biological Process (17 terms):
| GO ID | Term |
|---|
| GO:0007165 | signal transduction |
| GO:0007169 | cell surface receptor protein tyrosine kinase signaling pathway |
| GO:0016310 | phosphorylation |
| GO:0038083 | peptidyl-tyrosine autophosphorylation |
| GO:0046777 | protein autophosphorylation |
| GO:0042127 | regulation of cell population proliferation |
| GO:0042981 | regulation of apoptotic process |
| GO:0048666 | neuron development |
| GO:0045664 | regulation of neuron differentiation |
| GO:0021766 | hippocampus development |
| GO:0030534 | adult behavior |
| GO:0036269 | swimming behavior |
| GO:0006950 | response to stress |
| GO:0050995 | negative regulation of lipid catabolic process |
| GO:0060159 | regulation of dopamine receptor signaling pathway |
| GO:0097009 | energy homeostasis |
| GO:1900006 | positive regulation of dendrite development |
Molecular Function (7 terms):
| GO ID | Term |
|---|
| GO:0004713 | protein tyrosine kinase activity |
| GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
| GO:0005524 | ATP binding |
| GO:0008201 | heparin binding |
| GO:0030298 | receptor signaling protein tyrosine kinase activator activity |
| GO:0042802 | identical protein binding |
Cellular Component (5 terms):
| GO ID | Term |
|---|
| GO:0005886 | plasma membrane |
| GO:0032991 | protein-containing complex |
| GO:0043235 | receptor complex |
| GO:0070062 | extracellular exosome |
Section 8: Protein Interactions & Molecular Networks
STRING Interactions (Total: 3,930+)
TOP 50 Highest-Confidence Interacting Proteins:
| UniProt ID | Gene | Score | Description |
|---|
| Q9HC35 | EML4 | 997 | Echinoderm microtubule-associated protein-like 4 |
| P21246 | PTN | 991 | Pleiotrophin |
| P06748 | NPM1 | 990 | Nucleophosmin |
| P21741 | MDK | 971 | Midkine |
| P37173 | TGFBR2 | 947 | TGF-beta receptor type-2 |
| P36896 | ACVR1B | 929 | Activin receptor type-1B |
| P01116 | KRAS | 887 | GTPase KRas |
| P36897 | SMAD1 | 876 | Mothers against decapentaplegic homolog 1 |
| P31939 | ATIC | 867 | Bifunctional purine biosynthesis protein |
| P01111 | NRAS | 854 | GTPase NRas |
| P27037 | ACVR2A | 840 | Activin receptor type-2A |
| P29353 | SHC1 | 824 | SHC-transforming protein 1 |
| P28908 | TNFRSF8 | 823 | TNF receptor superfamily member 8 (CD30) |
| P33176 | KIF5B | 822 | Kinesin-1 heavy chain |
| Q9NZQ7 | ALK | 818 | ALK (self-interaction) |
| P06753 | TPM3 | 816 | Tropomyosin alpha-3 chain |
| P42336 | PIK3CA | 801 | PI3K catalytic subunit alpha |
| P29354 | SHC2 | 795 | SHC-transforming protein 2 |
| P18827 | SDC1 | 792 | Syndecan-1 |
| P04637 | TP53 | 772 | Cellular tumor antigen p53 |
BioGRID Interactions (Total: 741+)
Key Interaction Partners by Method:
| Interactor | Method | Function |
|---|
| SHC1 | Affinity Capture-Western | Adaptor protein |
| GRB2 | Affinity Capture-Western/MS | Adaptor protein |
| SRC | Affinity Capture-Western | Kinase |
| BCAR1 | Affinity Capture-MS | Adaptor protein |
| PTN | Reconstituted Complex | Ligand |
| JAK3 | Affinity Capture-Western | Kinase |
| PTPN11 | Proximity Label-MS | Phosphatase |
| PIK3R1 | Physical Association | PI3K regulatory |
| CDC37 | Proximity Label-MS | HSP90 co-chaperone |
| NUMB | Proximity Label-MS | Endocytosis |
IntAct Interactions (Total: 120+)
Key Validated Interactions:
| Interactor A | Interactor B | Type | Score |
|---|
| ALKAL1 | ALK | direct interaction | 0.66 |
| ALK | ALKAL2 | physical association | 0.56 |
| SHC1 | ALK | physical association | 0.69 |
| PIK3R1 | ALK | physical association | 0.59 |
| CRKL | ALK | physical association | 0.52 |
| NCK2 | ALK | physical association | 0.51 |
Protein Sequence Similarity (DIAMOND) - Total: 85
TOP 20 Homologous Proteins:
| UniProt ID | Top Identity (%) | Top Bitscore |
|---|
| Q63132 | 91.8 | 4356 |
| Q78DX7 | 91.8 | 4351 |
| Q61G93 | 84.2 | 4012 |
| Q8I7I5 | 84.2 | 3997 |
| P08922 | 79.5 | 3798 |
| P97793 | 86.6 | 2728 |
| P06213 | 99.5 | 2691 |
| P08069 | 97.7 | 2685 |
| P0DV84 | 89.1 | 2845 |
| Q60751 | 99.5 | 2783 |
| Q15208 | 97.8 | 2774 |
| Q64716 | 96.9 | 2562 |
| Q9WTL4 | 96.9 | 2562 |
| P14617 | 89.8 | 2397 |
| P14616 | 89.8 | 2388 |
| P08941 | 98.7 | 2378 |
| O73798 | 77.9 | 2091 |
| Q13308 | 92.6 | 1998 |
| Q5XJV6 | 84.5 | 1977 |
| Q96Q04 | 84.5 | 1974 |
Structural Similarity (ESM2) - Total: 50
TOP 20 Structurally Similar Proteins:
| UniProt ID | Similarity Score | Avg Similarity |
|---|
| O08628 | 0.9997 | 0.9698 |
| P23470 | 0.9995 | 0.9712 |
| Q05909 | 0.9995 | 0.9721 |
| Q13219 | 0.9997 | 0.9778 |
| Q61398 | 0.9997 | 0.9692 |
| Q80XH4 | 0.9997 | 0.9728 |
| O60383 | 0.9993 | 0.9807 |
| P0DV84 | 0.9993 | 0.9751 |
| P97793 | 0.9994 | 0.9751 |
| Q62849 | 0.9996 | 0.9773 |
| Q9QZL2 | 0.9996 | 0.9762 |
| O88199 | 0.9996 | 0.9757 |
| Q505J3 | 0.9997 | 0.9725 |
Section 9: Transcription Factor Regulatory Data
Note: ALK is NOT a transcription factor. It is a receptor tyrosine kinase.
Upstream Regulators (CollecTRI) - Total: 8
Transcription factors that regulate ALK expression:
| TF Gene | Regulation | Confidence |
|---|
| PHOX2B | Activation | High |
| AP1 | - | High |
| ESR1 | - | High |
| JUNB | - | High |
| STAT5A | - | High |
| TXK | - | High |
| CEBPB | - | Low |
| TCF23 | - | Low |
| Key Regulatory Insight |
|---|
| PHOX2B is a confirmed transcriptional activator of ALK, particularly relevant in neuroblastoma where PHOX2B mutations can affect ALK expression. | |
| Drug & Pharmacology Data** |
ChEMBL Target Information
| Target ID | Target Name | Target Type |
|---|
| CHEMBL4247 | ALK tyrosine kinase receptor | SINGLE PROTEIN |
| CHEMBL2111387 | NPM/ALK | CHIMERIC PROTEIN |
| CHEMBL3883330 | EML4-ALK | CHIMERIC PROTEIN |
Approved ALK Inhibitors (Phase 4)
| ChEMBL ID | Drug Name | Development Phase |
|---|
| CHEMBL601719 | CRIZOTINIB | 4 (Approved) |
| CHEMBL1738797 | ALECTINIB | 4 (Approved) |
| CHEMBL2403108 | CERITINIB | 4 (Approved) |
| CHEMBL3545311 | BRIGATINIB | 4 (Approved) |
| CHEMBL3286830 | LORLATINIB | 4 (Approved) |
| CHEMBL1983268 | ENTRECTINIB | 4 (Approved) |
| CHEMBL4298138 | REPOTRECTINIB | 4 (Approved) |
Other Kinase Inhibitors with ALK Activity (Phase 4)
| ChEMBL ID | Drug Name | Primary Target | Phase |
|---|
| CHEMBL535 | SUNITINIB | Multi-kinase | 4 |
| CHEMBL477772 | PAZOPANIB | Multi-kinase | 4 |
| CHEMBL24828 | VANDETANIB | Multi-kinase | 4 |
| CHEMBL288441 | BOSUTINIB | BCR-ABL | 4 |
| CHEMBL553 | ERLOTINIB | EGFR | 4 |
| CHEMBL3353410 | OSIMERTINIB | EGFR | 4 |
| CHEMBL189963 | PALBOCICLIB | CDK4/6 | 4 |
| CHEMBL1789941 | RUXOLITINIB | JAK1/2 | 4 |
| CHEMBL1287853 | FEDRATINIB | JAK2 | 4 |
| CHEMBL3622821 | UPADACITINIB | JAK1 | 4 |
| CHEMBL502835 | NINTEDANIB | Multi-kinase | 4 |
| CHEMBL3301622 | GILTERITINIB | FLT3/AXL | 4 |
| CHEMBL608533 | MIDOSTAURIN | Multi-kinase | 4 |
Phase 3 Inhibitors
| ChEMBL ID | Drug Name | Phase |
|---|
| CHEMBL50 | QUERCETIN | 3 |
| CHEMBL223360 | LINIFANIB | 3 |
| CHEMBL276711 | SEMAXANIB | 3 |
| CHEMBL491473 | CEDIRANIB | 3 |
| CHEMBL522892 | DOVITINIB | 3 |
| CHEMBL3545308 | ROCILETINIB | 3 |
| CHEMBL1879463 | DACTOLISIB | 3 |
| CHEMBL428690 | ALVOCIDIB | 3 |
| CHEMBL603469 | LESTAURTINIB | 3 |
| CHEMBL31965 | CANERTINIB | 3 |
PharmGKB
| PharmGKB ID | Symbol | VIP Gene | CPIC Guideline |
|---|
| PA24719 | ALK | ✓ YES | No |
Section 11: Expression Profiles
Bgee Expression Summary
| Property | Value |
|---|
| Expression Breadth | Ubiquitous |
| Total Present Calls | 181 |
| Total Absent Calls | 86 |
| Total Conditions | 267 |
| Max Expression Score | 85.61 |
| Average Expression Score | 54.69 |
| Gold Quality Count | 214 |
TOP 30 Tissues/Cell Types by Expression
| Tissue/Cell Type | Expression | Score | Quality |
|---|
| Sperm | Present | 85.61 | Gold |
| Male germ cell | Present | 85.51 | Gold |
| Male germ line stem cell (testis) | Present | 85.22 | Gold |
| Ventral tegmental area | Present | 78.37 | Gold |
| Superior vestibular nucleus | Present | 77.39 | Gold |
| Medial globus pallidus | Present | 77.03 | Silver |
| Subthalamic nucleus | Present | 76.80 | Silver |
| Buccal mucosa cell | Present | 76.70 | Silver |
| Dorsal plus ventral thalamus | Present | 76.44 | Silver |
| Globus pallidus | Present | 76.35 | Silver |
| Brodmann area 23 | Present | 75.67 | Gold |
| Inferior vagus X ganglion | Present | 75.22 | Silver |
| Middle temporal gyrus | Present | 74.13 | Gold |
| Trigeminal ganglion | Present | 73.35 | Silver |
| Dorsal root ganglion | Present | 73.10 | Silver |
Tissues with LOW/ABSENT Expression
| Tissue | Expression | Score |
|---|
| Type B pancreatic cell | Absent | 83.34 |
| Olfactory bulb | Absent | 83.23 |
| Cervix squamous epithelium | Absent | 77.67 |
| Diaphragm | Absent | 77.39 |
| Thymus | Absent | 76.19 |
| Cerebellar vermis | Absent | 74.78 |
Single-Cell Expression Data
| Dataset ID | Description | Species | Cell Count |
|---|
| E-ANND-2 | GTEx: snRNAseq atlas | Homo sapiens | 209,126 |
Section 12: Disease Associations
Mendelian/Monogenic Disease (GenCC)
| Disease | Classification | Inheritance | Evidence |
|---|
| Neuroblastoma, susceptibility to, 3 (OMIM:613014) | Definitive | Autosomal dominant | G2P |
| Neuroblastoma, susceptibility to, 3 (OMIM:613014) | Strong | Autosomal dominant | Ambry, Labcorp |
Orphanet Disease Associations (Total: 8)
| Orphanet ID | Disease Name | Type |
|---|
| 635 | Neuroblastoma | Disease |
| 251877 | Ganglioneuroblastoma | Disease |
| 251992 | Ganglioneuroma | Disease |
| 300895 | ALK-positive anaplastic large cell lymphoma | Histopathological subtype |
| 364043 | ALK-positive large B-cell lymphoma | Disease |
| 178342 | Inflammatory myofibroblastic tumor | Disease |
| 146 | Differentiated thyroid carcinoma | Disease |
| 626 | Large/giant congenital melanocytic nevus | Disease |
MONDO Disease Associations
| MONDO ID | Disease Name |
|---|
| MONDO:0020325 | Anaplastic large cell lymphoma |
HPO Phenotype Associations (Total: 68)
Cancer/Tumor-Related Phenotypes:
| HPO ID | Phenotype |
|---|
| HP:0003006 | Neuroblastoma |
| HP:0003005 | Ganglioneuroma |
| HP:0100631 | Neoplasm of the adrenal gland |
| HP:0004375 | Neoplasm of the nervous system |
| HP:0012056 | Cutaneous melanoma |
| HP:0005600 | Congenital giant melanocytic nevus |
Neurological Phenotypes:
| HPO ID | Phenotype |
|---|
| HP:0001250 | Seizure |
| HP:0001251 | Ataxia |
| HP:0001336 | Myoclonus |
| HP:0012758 | Neurodevelopmental delay |
| HP:0010543 | Opsoclonus |
| HP:0007110 | Central hypoventilation |
| HP:0002277 | Horner syndrome |
Hematological/Systemic Phenotypes:
| HPO ID | Phenotype |
|---|
| HP:0001873 | Thrombocytopenia |
| HP:0001903 | Anemia |
| HP:0001892 | Abnormal bleeding |
| HP:0001945 | Fever |
| HP:0002716 | Lymphadenopathy |
GWAS Associations (Total: 15)
| Study ID | Trait | P-value | Chr |
|---|
| GCST008758_64 | Pre-treatment viral load in HIV-1 infection | 7.0e-18 | 2 |
| GCST008295_43 | Number of decayed/missing/filled tooth surfaces | 2.0e-09 | 2 |
| GCST011346_32 | Total cholesterol levels | 4.0e-09 | 2 |
| GCST011347_56 | Low density lipoprotein cholesterol levels | 4.0e-08 | 2 |
| GCST010989_247 | Body size at age 10 | 3.0e-08 | 2 |
| GCST008306_9 | Dentures | 6.0e-08 | 2 |
| GCST008386_3 | Carbamazepine-induced serious cutaneous adverse reaction | 5.0e-08 | 2 |
| GCST002726_14 | Glucose homeostasis traits | 3.0e-06 | 2 |
| GCST002783_418 | Body mass index | 8.0e-06 | 2 |
| GCST003095_3 | Adiponectin levels (BMI-adjusted) | 7.0e-06 | 2 |
| GCST003670_7 | Systolic blood pressure | 1.0e-06 | 2 |
| GCST008176_8 | Gestational age at birth | 4.0e-06 | 2 |
| GCST008384_3 | Carbamazepine-induced DRESS | 1.0e-06 | 2 |
| GCST008551_19 | Simvastatin-induced myopathy | 5.0e-06 | 2 |
| GCST90000582_8 | Spontaneous coronary artery dissection | 8.0e-06 | 2 |
SUMMARY STATISTICS
| Category | Count |
|---|
| Gene Identifiers | 5 (HGNC, Ensembl, Entrez, OMIM, UniProt) |
| Transcripts (Ensembl) | 7 |
| RefSeq Transcripts | 2 (human) |
| CCDS | 2 |
| Exons (canonical) | 29 |
| UniProt Entries | 1 (reviewed) |
| Protein Domains | 13 |
| PDB Structures | 79 |
| Orthologs | 4 (mouse, rat, zebrafish, fly) |
| ClinVar Variants | 6,175 |
| Pathogenic Variants | 19 |
| Likely Pathogenic Variants | 7 |
| AlphaMissense Predictions | 10,546 |
| SpliceAI Predictions | 6,693 |
| Reactome Pathways | 11 |
| GO Annotations | 29 |
| STRING Interactions | 3,930+ |
| BioGRID Interactions | 741+ |
| IntAct Interactions | 120+ |
| Sequence Homologs | 85 |
| Structural Homologs | 50 |
| Approved ALK Inhibitors | 7 |
| Phase 3+ Drugs | 32 |
| Orphanet Diseases | 8 |
| HPO Phenotypes | 68 |
| GWAS Associations | 15 |
This reference document was compiled using BioTree cross-database integration platform, covering 70+ biological databases.